GHRP-6

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the first synthetic hexapeptides discovered to possess potent growth hormone-releasing activity. It was developed in the 1980s by Cyril Bowers and colleagues at Tulane University as part of a systematic effort to identify short peptide sequences capable of stimulating GH secretion from the anterior pituitary gland.

GHRP-6 was instrumental in the discovery of the growth hormone secretagogue receptor (GHS-R), which was later identified as the receptor for the endogenous hormone ghrelin. In this sense, GHRP-6 served as a pharmacological tool that predicted the existence of ghrelin years before the hormone was actually isolated by Kojima et al. in 1999. GHRP-6 is often classified as a ghrelin mimetic because it binds to and activates the same receptor.

Unlike the later-generation secretagogue Ipamorelin, GHRP-6 has a broader pharmacological profile. In addition to robustly stimulating GH release, it increases appetite through central ghrelin receptor activation, modestly elevates cortisol and prolactin at higher doses, and has demonstrated direct cardioprotective and anti-fibrotic properties independent of its GH-stimulating effects.

Mechanism of Action

GHRP-6 acts through multiple receptor-mediated pathways to stimulate growth hormone release and exert additional peripheral effects.

GHS-R1a Activation

The primary mechanism of GHRP-6 involves agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a). This G-protein coupled receptor activates the phospholipase C-IP3-diacylglycerol pathway, leading to intracellular calcium mobilization and subsequent GH exocytosis from somatotroph cells. GHRP-6 also suppresses somatostatin signaling, removing a key inhibitory brake on GH secretion.

Hypothalamic Effects

In addition to direct pituitary actions, GHRP-6 acts at the hypothalamic level to stimulate GHRH release from arcuate nucleus neurons. This dual-site action (hypothalamus and pituitary) amplifies the GH response beyond what direct pituitary stimulation alone would achieve. The hypothalamic component also explains GHRP-6’s orexigenic (appetite-stimulating) effects, as GHS-R1a receptors in the arcuate nucleus and ventromedial hypothalamus are involved in feeding behavior regulation.

Cardioprotective Mechanisms

Research has revealed GH-independent cardioprotective effects of GHRP-6. These appear to involve activation of the PI3K/Akt survival pathway in cardiomyocytes, suppression of pro-inflammatory cytokine production, and reduction of reactive oxygen species generation. GHS-R1a expression has been confirmed in cardiac tissue, providing a molecular basis for these direct cardiac effects.

Research Summary

GH Secretion Studies

Bowers et al. (1991), publishing in Endocrinology, provided the foundational characterization of GHRP-6 as a GH secretagogue. Intravenous administration in humans produced a rapid, dose-dependent increase in serum GH with a peak at 15-30 minutes post-injection. The GH response was amplified approximately 10-fold when GHRP-6 was co-administered with GHRH, demonstrating the synergistic interaction between these two pathways.

Cardioprotection Research

Berlanga et al. (2007), in a study published in Clinical and Experimental Pharmacology and Physiology, demonstrated that GHRP-6 significantly reduced myocardial infarct size and preserved left ventricular function in a rat ischemia-reperfusion model. The cardioprotective effect was associated with reduced oxidative stress markers and inflammatory cytokines. A 2015 follow-up study by the same group in Peptides showed that chronic GHRP-6 administration attenuated liver fibrosis in a carbon tetrachloride-induced model.

Appetite and Metabolism

Arvat et al. (2001), publishing in the Journal of Clinical Endocrinology & Metabolism, systematically compared the neuroendocrine effects of GHRP-6 with those of hexarelin and ghrelin in humans. GHRP-6 produced robust GH release and a significant increase in food intake within 60 minutes of administration. Cortisol and prolactin elevations were modest and transient, typically normalizing within 2-3 hours.

Wound Healing

Diaz-Rodriguez et al. (2012), in Growth Hormone & IGF Research, investigated GHRP-6 in a diabetic wound healing model and found that topical application promoted granulation tissue formation, angiogenesis, and epithelialization. These wound-healing effects appeared to involve both GH-dependent and GH-independent mechanisms, including direct stimulation of fibroblast proliferation and collagen synthesis.

Dosing in Published Research

GHRP-6 was the first growth-hormone-releasing peptide identified and has been used as a research tool in human pharmacology. It is not an approved medicine and has no labeled dose. In a Phase 1 study, single intravenous doses were tested across a range from 1 to 400 micrograms per kilogram of body weight; growth-hormone release approached saturation at roughly 1 microgram per kilogram. These figures describe what was administered in that specific study.

Safety and Side Effects

GHRP-6 has not been characterized by adequate human safety trials. Beyond the general growth hormone secretagogue effects of fluid retention, altered insulin sensitivity and blood glucose, headache, and injection-site reactions, GHRP-6 has two prominent features: it is a strong ghrelin-receptor agonist that produces intense hunger, and it raises cortisol and prolactin more than the more selective secretagogues do. Sustained elevation of growth hormone and IGF-1 carries the theoretical metabolic and proliferative concerns associated with growth hormone excess. Long-term human safety data are unavailable, and unregulated material is of uncertain identity and purity.

Current Research Status

GHRP-6 was studied in early clinical research but was never approved by the FDA or any major regulatory agency for any use. It is prohibited in sport by the World Anti-Doping Agency. It is sold only as a research chemical and should be regarded as investigational.

Frequently Asked Questions